Skip to main content
. 2020 Jul 25;20:167. doi: 10.1186/s12893-020-00824-6

Table 2.

Oncology outcomes of the included studies

Author year TS (cm) TL (R/L) PP (Pn/Tn) PM (n) PR (n) FT (Month)
Tiberio-2008a 4.0 (2.2-6.0) 8/5 13/13 0 0 18
Tiberio-2008b 4.1 (2.5-6.0) 5/4 9/9 0 0 18
Inabnet-2000a 4.1±1.2 8/3 11/11 0 0 37 (26-51)
Inabnet-2000b 4.6±1.2 3/8 11/11 0 0 52 (27-72)
Kim-2004a 5.2 ± 2.0 9/6 15/15 0 NR 22
Kim-2004b 6.4 ± 2.6 5/4 9/9 0 NR 36
Zhu-2019a 7.76± 2.02 29/15 NR 0 NR 40.9 (9.5, 102.5)
Zhu-2019b 7.92± 1.98 28/16 NR 0 NR 70.8 (4.0, 117.5)
Bai-2019a 7.8 (7.0-8.6) 34/30 NR 0 3 36
Bai-2019b 8.2 (7.0-10.0) 30/34 NR 2 1 65
Sprung-2000a NR NR 14/14 0 NR NR
Sprung-2000b NR NR 20/20 0 NR NR
Tanaka-2000a 3.5 (3.0-5.0) NR NR 0 NR NR
Tanaka-2000b 4.1 (2.3-6.2) 2/4 NR 0 NR NR
Lang-2008a 4.5 ± 2.0 25/28 53/53 0 0 5-36
Lang-2008b 4.9 ± 2.6 27/23 53/53 0 0 5-36
Edwin-2001a 6.0 (3.0-11.0) 1/5 6/6 0 NR NR
Edwin-2001b 6.0 (2.7–8.0) 4/4 8/8 0 NR NR
Wang-2011a 4.06 ± 1.47 10/16 NR 0 0 25 (20-40)
Wang-2011b 5.61 ± 2.74 13/10 NR 0 0 25 (20-40)
Davies-2004a NR 3/9 11/11 0 NR NR
Davies-2004b NR 5/7 12/12 0 NR NR
Kazaryan-2004a 6.4 ± 2.6 3/6 9/9 0 NR NR
Kazaryan-2004b 5.6 ± 1.9 10/12 22/22 0 NR NR
Song-2012a 1.5-4.0 11/12 23/23 0 0 6-48
Song-2012b 2.0-5.5 11/14 25/25 0 0 6-48
Barband-2008a 3.8±0.77 6/4 NR 0 NR NR
Barband-2008b 5.8±3.1 NR NR 0 NR NR

FT Follow-up time, L Left, NR Not reported, PM Perioperative mortality, Pn The number of pheochromocytomas, PR Postoperative recurrence, PP Postoperative pathology, R Right, TL Tumor laterality, Tn The number of patients, TS Tumor size

aPatients in this group underwent laparoscopic surgery

bPatients in this group underwent open surgery